


Searching News Database: Volociximab
HSMN NewsFeed - 12 Mar 2007
Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients With Relapsing Multiple Sclerosis
Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients With Relapsing Multiple Sclerosis
Additional items found! 2
Members Archive contains
2 additional stories matching:
Volociximab
(Password required)
Volociximab
(Password required)
